ReviewCureus2025
A Comparative Effectiveness of Intravenous Fluids and Insulin Regimens in the Acute Management of Diabetic Ketoacidosis (DKA) and Hypoglycemia: A Systematic Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic ketoacidosis (DKA) and hypoglycemia are acute metabolic emergencies requiring prompt and effective management in both adult and pediatric populations. Despite established protocols, variability in intravenous fluid and insulin regimens persists, necessitating a comprehensive evaluation of their comparative effectiveness across age groups. This systematic review aims to synthesize evidence on the efficacy and safety of different fluid and insulin strategies in managing DKA and hypoglycemia in diverse patient populations. Following PRISMA 2020 guidelines, a systematic search was conducted across PubMed, Embase, Web of Science, and Scopus. Nine studies (five randomized controlled trials (RCTs) and four cohort studies) were included after screening 227 records. Risk of bias was assessed using Cochrane RoB 2 for RCTs and the Newcastle-Ottawa Scale for cohort studies. Data were synthesized narratively due to clinical heterogeneity. Early subcutaneous insulin glargine with intravenous insulin reduced DKA resolution time (9.89 ± 3.81 vs. 12.73 ± 5.37 hours; p = 0.022) and hospital stay (4.75 vs. 15.25 days; p = 0.024) compared to intravenous insulin alone. Low-dose insulin (0.05 unit/kg/hour) in pediatric DKA showed comparable efficacy to the standard dose (0.1 unit/kg/hour), with fewer hypoglycemia (3.3% vs. 13.3%) and hypokalemia events (30% vs. 43.3%). Plasmalyte-148 accelerated metabolic acidosis resolution vs. sodium chloride (69% vs. 36% at 24 hours; p = 0.002). For hypoglycemia, 10% and 50% dextrose had similar efficacy, but 50% dextrose required higher doses and caused elevated post-treatment glucose (151.9 vs. 124.6 mg/dL; p = 0.001). Subcutaneous insulin protocols, low-dose insulin infusions, and balanced crystalloids optimize DKA management, while lower dextrose concentrations may suffice for hypoglycemia. Future research should prioritize multicenter RCTs to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.